Lenalidomidum Stada Arzneimittel Ag

Lenalidomide, the active ingredient in Lenalidomidum Stada Arzneimittel Ag, is an immunomodulatory drug presented as a tablet for oral use. It treats certain blood cancers such as multiple myeloma, myelodysplastic syndromes, and mantle cell lymphoma in adult patients.

GNH USA supplies Lenalidomidum Stada Arzneimittel Ag as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, oncology centres, and pharmacies worldwide.

Lenalidomide is used in the treatment of hematologic malignancies and related disorders.

- Multiple Myeloma: improves progression‑free survival and overall response rates in patients with relapsed or refractory disease. - Myelodysplastic Syndromes: reduces transfusion dependence and improves blood counts in patients with del(5q) cytogenetic abnormality. - Mantle Cell Lymphoma: contributes to disease control in patients with relapsed or refractory mantle cell lymphoma.

Lenalidomide may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Fatigue: persistent tiredness affecting daily activities. - Diarrhea: loose stools that may require fluid replacement. - Nausea: feeling of sickness often accompanied by loss of appetite. - Rash: mild skin eruptions or itching.

Serious or Rare Side Effects: - Thromboembolic events: deep vein thrombosis or pulmonary embolism requiring immediate medical attention. - Severe neutropenia: markedly reduced neutrophil count increasing infection risk. - Secondary primary malignancies: emergence of new cancers distinct from the original disease.

When prescribing lenalidomide, clinicians should consider several safety precautions.

- Pregnancy risk: contraindicated in pregnancy due to teratogenicity; ensure effective contraception. - Thrombosis prophylaxis: assess need for anticoagulation in patients with additional risk factors. - Hematologic monitoring: perform regular complete blood counts to detect neutropenia or anemia. - Renal function: adjust use in patients with impaired kidney function and monitor creatinine. - Drug interactions: review concomitant medications for potential CYP or immunosuppressive interactions. - Store at ambient temperature: keep below 25 °C in the original container, protect from moisture and light.

Lenalidomide can interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inducers: agents such as rifampicin may markedly reduce lenalidomide exposure. - Anticoagulants: concurrent use with warfarin can increase bleeding risk; close monitoring required.

Moderate Interactions (Monitor Closely): - Immunosuppressants: drugs like cyclosporine may enhance immunomodulatory effects, requiring dose adjustment. - Live vaccines: administration may be less effective and increase infection risk; avoid during therapy. - NSAIDs: may increase risk of renal impairment when combined with lenalidomide in susceptible patients.